log  
logo
a Journal of Postdoctoral Research and Postdoctoral Affairs.
logo
    ISSN : 2328-9791 Contact Us
left right
 
 
Development of metallo-enzyme inhibitors to overcome Pseudomonas aeruginosa antibiotic-re
     
 
Author(s) : Gemma S, Brogi S, Brindisi M, Vallone A, De Luca F, Docquier JD
Address : Department of Biotechnology, Chemistry, and Pharmacy, Department of Medical Biotechnology, University of Siena, Italy.
University of Siena
Info@PostdocJournal.Com

Background. Pseudomonas aeruginosa is the most dominant pathogen associated with adverse clinical outcomes in patients with cystic fibrosis (CF). Anti-pseudomonal β-lactams are the mainstay of therapy for the treatment of chronic P. aeruginosa lung infections CF patients. Unfortunately, this pathogen becomes increasingly resistant to available antibiotics and the global dissemination of multidrug resistant P. aeruginosa strains with acquired carbapenemase genes is a public health concern. 

Hypothesis and objectives. One important mechanism of resistance to β-lactams is the production of one or more β-lactamase(s), belonging to either the active serine enzymes or the metallo-β-lactamases (MBLs), which efficiently inactivate these antibiotics. Acquired MBLs are important resistance factors in P. aeruginosa, conferring resistance to most β-lactams, including the last-resort carbapenems. Considering the increasing prevalence of MBL-producing strains in CF patients (as high as >50% in some settings), our goal is to perform the preclinical investigation and optimization of MBLs inhibitors to be used in combination with currently-available β-lactam antibiotics

 
btm
 
Discussion Board
 
Comments
 
     
btm
 
 
 
top
 
 
 
btm
top
btm

 
submit_article Announcements
 
submit_article Submit Your Article
 
submit_article Post your Job
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here